Efficacy of danofloxacin 18% injectable solution in the treatment of Escherichia coli diarrhoea in young calves in Europe |
| |
Authors: | Sunderland Simon J Sarasola P Rowan T G Giles C J Smith D G |
| |
Affiliation: | Pfizer Animal Health Group, Pfizer Ltd., Sandwich, Kent CT13 9NJ, UK. simon_sunderland@sandwich.pfizer.com |
| |
Abstract: | The efficacy of danofloxacin 18% against naturally occurring Escherichia coli diarrhoea was investigated in calves at seven European sites. Treatment commenced on day 0, with either a single subcutaneous injection of danofloxacin 18% (n=267) at 6 mg/kg repeated on day 2 if required, or reference product containing baquiloprim/sulphadimidine (n=37) or gentamicin (n=98) administered as recommended. E. coli was isolated from 90% to 100% of calves pre-treatment, and the prevalence of serotypes K99 and F41 was 8-46% and 46-92%, respectively. In both treatments, the majority of calves (93.2-93.9%) showed clinical improvement and completed the studies. There were significant reductions for both treatments, in severity of clinical signs on days 4 and 10 compared to day 0 (P<0.0001), and between days 4 and 10 (P<0.05), but no significant differences between treatments (P>0.05). Danofloxacin 18% was clinically safe, and as effective as the reference products in the treatment of E. coli diarrhoea in calves. |
| |
Keywords: | E. coli. Danofloxacin Diarrhoea Colibacillosis |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|